PAVmed Inc. (PAVM) Set to Announce Quarterly Earnings on Thursday
PAVmed Inc. (NASDAQ:PAVM) is scheduled to be issuing its n/a quarterly earnings data after the market closes on Thursday, November 16th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. On average, analysts expect PAVmed to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
PAVmed Inc. (NASDAQ:PAVM) opened at $3.90 on Wednesday. PAVmed Inc. has a 52-week low of $2.54 and a 52-week high of $10.72.
Several research analysts have weighed in on PAVM shares. Dawson James reiterated a “buy” rating and issued a $10.10 price target on shares of PAVmed in a research report on Tuesday, September 5th. ValuEngine upgraded shares of PAVmed from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
In other news, CFO Dennis M. Mcgrath acquired 6,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of $4.21 per share, for a total transaction of $25,260.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have bought a total of 13,950 shares of company stock worth $57,653 over the last 90 days. Insiders own 79.30% of the company’s stock.
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.